Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
autosomal dominant) Psammomatous melanotic schwannoma: Mass effects Lentigines (65%) of face, lips, caruncle, and female genitalia Myxomas of heart (65%), skin (25%), breast (20%) Blue nevi of extremities and trunk Endocrine overactivity Cushing syndrome (25%): Pigmented nodular adrenocortical disease Acromegaly: Pituitary adenoma, mammosomatotrophic type Precocious puberty (30%): Large cell Sertoli tumor of testis Treatment Surgical approaches Resection with tumor-free margins for all lesions Prognosis Benign Recurrence in subtotal resection Malignant Metastasis Distinguish metastases from 2nd primary Prognosis same in conventional and psammomatous variants 15% die of tumor IMAGE FINDINGS MR Findings CT Findings Calcification/ossification on CT in some psammomatous tumors MACROSCOPIC FEATURES General Features 0.5-26 cm (median: 5 cm) Circumscribed Round to sausage-shaped Spinal nerve root tumors: Dumbbell-shaped Occasionally lobulated or cystic No encapsulation Occasionally thin collagen layer with soft tissue invasion Effects of bone Erosion (benign tumors) Invasive destruction (malignant tumors) Cut surface gray to tar black Infrequently cystic Occasional hemorrhage or necrosis Occasional subcapsular grittiness (psammomatous variant) Soft to rubbery
Muscle protects against diabetes, liver and cholesterol issues
About this article Cite this article Apperloo, E.M., Gorriz, J.L., Soler, M.J
Its use is investigational, and it is not approved by any regulatory authority for the treatment of any specific medical condition
BPC-157 Is Classified as an Unapproved New Drug According to the FDAs definition, any substance that claims to treat, diagnose, cure, or prevent disease is considered a drug. If it hasnt gone through the FDAs rigorous review and approval process, its classified as unapproved and illegal to market or distribute for human consumption
)
US$ 20.10
US$ 25.08
US$ 27.24
